

Table SI. Summary of clinician-reported (Static Physician's Global Assessment of Genitalia [sPGA-G] and overall sPGA scores) and patient-reported (Patients Global Assessment of Genital Psoriasis scores) outcomes at the visit when the decision was made to increase dosing frequency to ixekizumab (IXE) every 2 weeks in patients randomized to IXE

	IXE patients who stepped up to IXE Q2W n = 25 ^a n (%)
sPGA-G	
=0	7 (28.0)
=1	1 (4.0)
=2	9 (36.0)
=3	6 (24.0)
=4	2 (8.0)
=5	0
Overall sPGA	
=0	0
=1	8 (32.0)
=2	10 (40.0)
=3	6 (24.0)
=4	0
=5	1 (4.0)
PatGA-Genital	
=0	6 (24.0)
=1	7 (28.0)
=2	2 (8.0)
=3	6 (24.0)
=4	2 (8.0)
=5	2 (8.0)

^aIncludes all patients initially randomized to IXE Q2W at Week 0 who received at least 1 dose of IXE during the open-label treatment period and increased dosing frequency from IXE Q4W to IXE Q2W during study visits at Weeks 24, 28, or 40. Q2W: every 2 weeks; Q4W: every 4 weeks; PatGA-Genital: Patient's Global Assessment of Genital Psoriasis; sPGA: static Physician's Global Assessment; sPGA-G: sPGA of Genitalia.